Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?

Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor ...
The Motley Fool

Is Pfizer's 5.7% Dividend Yield Worth the Risk?

This significant decline primarily stems from the sales slump of Pfizer's once-booming COVID-19 franchise. However, amid this key challenge, Pfizer's current valuation may present an intriguing ...